Top broker tips CSL (ASX:CSL) share price to climb to $340

Time to buy CSL shares?
The post Top broker tips CSL (ASX:CSL) share price to climb to $340 appeared first on The Motley Fool Australia. –

The CSL Limited (ASX: CSL) share price has been an underperforming in 2021.

Since the start of the year, the biotherapeutics giant’s shares have gained just under 3%.

This compares to an 11% gain by the S&P/ASX 200 Index (ASX: XJO) over the same period.

Is the CSL share price underperformance a buying opportunity?

One leading broker that appears to see the underperformance in the CSL share price this year as a buying opportunity is Citi.

According to a recent note, the broker has upgraded the company’s shares to a buy rating with a $340.00 price target.

Based on the current CSL share price of $292.85, this implies potential upside of 16.1% over the next 12 months. Citi also expects a dividend yield of ~1.2% in FY 2022, bringing the total return on offer to almost 17.5%.

What did Citi say?

Citi has been looking at the company’s acquisition of Vifor Pharma for US$11.7 billion.

While it notes that the transaction value appears reasonably full, it highlights that the Swiss-based biotech giant’s revenues have been subdued because of the pandemic. Furthermore, a number of new products have the potential to boost its revenues in the near future.

All in all, Citi believes the Vifor acquisition is likely to be ~9% earnings per share accretive (pre-amortisation) in FY 2023.

It commented: “CSL has announced that the acquisition of Vifor Pharma – it is acquiring the company at CHF165.5 (US$179.25), a ~65% premium to where the stock was trading pre bid discussion and a ~37% premium to the three-month VWAP. We calculate the acquisition to be ~9% accretive to NPATA per share (NPAT before acquisition-related amortization) – a proxy for cash flow. Including amortization, the transaction is expected to be “modestly accretive” to EPS.”

“CSL is acquiring Vifor Pharma at roughly ~14x FY23 EBITDA (including the full run rate of US$75m in cost synergies). Time will tell if CSL has paid a full price given that the revenue is currently subdued because of the pandemic, and several new products are yet to launch, but the transaction should be ROIC dilutive in FY23. CSL’s management team presented the transaction as being strategically aligned with the existing business,” Citi concluded.

The post Top broker tips CSL (ASX:CSL) share price to climb to $340 appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

3 five-star ASX shares to buy in 2022

Where are CSL (ASX:CSL) shares headed in 2022?

2 high quality ASX 200 shares with huge upside potential

Here are the top 10 ASX shares today

Interested in the $750m CSL (ASX:CSL) share purchase plan? Here are the details

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!